Skip to content

You can have confidence in your biosimilar medicines

Learn more
Switching to biosimilars is safe and effective for patients
Learn more
Previous
Next

Who we are

Biosimilars Canada is a national association representing the biosimilar medicines industry in Canada. We provide leadership in educating Canadian stakeholders about the safety and efficacy of biosimilar medicines, and advocate for policies that support their timely approval, reimbursement, market acceptance and expanded use.

About Biosimilars

As patents for original brand biologic medicines expire other manufacturers can produce new versions called biosimilars. Health Canada authorizes biosimilars for sale using the same rigorous regulatory standards as for all other biologic drugs, and there are no clinically meaningful differences in efficacy and safety between a biosimilar and the original brand biologic medicine.

Resources

Learn more about biosimilars and their benefits for patients and healthcare systems.

Latest news

Update on biosimilars in Canada

The law firm Smart & Biggar recently published an overview of some key developments for biosimilars in Canada, including approvals, pending submissions and litigation. Health Canada has approved 36 biosimilars to date and has 16 biosimilar submissions under review.

Read more

Alberta Adds Humira Adalimumab to Biosimilar Switching Program

Biosimilars Canada today congratulated the Province of Alberta and Health Minister Tyler Shandro on the expansion of the province’s biosimilar switching program to include Humira adalimumab.
Read more

Mandatory biosimilar switching pays off for Canada

For Alberta and Green Shield Canada savings are beginning to add up from switching initiatives for multiple reference biologics, reports the American Journal of Managed Care (AJMC).

Read more